2cureX AB
SSTO:2CUREX0.42
SEK
-0.06
(-12.13%)
ISIN
SE0010468124
Return %
Stock
S&P 500
1Y
-82.79
14.20
3Y
-88.92
81.12
5Y
-97.56
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Semi-annual Revenue
SEK
•
in mil. unless spec.Semi-annual Earnings Per Share
SEK
•
in mil. unless spec.Semi-annual Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Ole Thastrup
- Full Time Employees
- 14
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Lilla Strandgatan 19, 261 29 Copenhagen Denmark 261 29
- IPO Date
- Nov 24, 2017
- Website
- 2curex.com
- Similar Companies
- Business
- 2cureX AB (publ) (2CUREX.ST) operates as a Sweden-domiciled medtech and biotechnology company focused on precision oncology diagnostics; it develops and commercializes IndiTreat, an in-vitro diagnostic (IVD) test utilizing proprietary tumoroid technology to create three-dimensional microtumors from patient samples, enabling oncologists to predict tumor response and resistance to chemotherapies and experimental treatments for personalized cancer therapy selection. Core products include IndiTreat-CRC for colorectal cancer, IndiTreat-OVA for ovarian cancer, IndiTreat-KDN for kidney cancer, and expansions into pancreatic cancer and additional indications; the company also offers IndiTreat Specimen Collection Kit and IndiTreat Shipping Container, both CE-marked under the new IVD regulation, alongside clinical testing services from its Copenhagen laboratory and research/consulting services. Founded in 2006 and headquartered in Copenhagen, Denmark, with operations through subsidiary 2cureX A/S and affiliate 2cureX GmbH in Germany, it serves healthcare providers, patients, and pharmaceutical partners across 20 European countries including the UK, Sweden, Germany, and Denmark via a Direct-to-Patient model and distributor network. Recent developments encompass the launch of "Operation Twin Code" with new investors including Kinled Group and Koodos Ltd for leadership transition, AI integration, and global roadmap; validation of Direct-to-Patient IndiTreat access in the UK, Sweden, and Germany; strategic PreComb Therapeutics AG partnership for pharma-driven clinical trials in colorectal, pancreatic, ovarian, and further cancers; pursuit of full CE-IVDR approval for IndiTreat by 2cureX A/S expected later in 2025; appointment of Mangold Corporate Finance as liquidity provider and Mangold Fondkommission AB as certified adviser; improved financial discipline reducing H1 2025 pre-tax loss to -1,951 KSEK from -9,560 KSEK; and a warrant program for board members resolved in December 2024. The company maintains Nasdaq First North Growth Market listing under ticker 2CUREX with 25.1 million shares outstanding as of mid-2025, reporting minimal net sales of 25 KSEK (TTM) and cash reserves of 5.1 million SEK.